Intrinsic Imaging
Neuroradiologist in front of brain MRI and DTI tractography monitors

Central Nervous System Imaging Core Lab Division

Intrinsic Imaging provides imaging core lab services in support of central nervous system (CNS) clinical trials. In neurological, neurodegenerative, cerebrovascular, psychiatric and spinal indications, our subspecialty neuroradiologists apply advanced quantitative neuroimaging and standardized imaging methods, providing sponsors with a sound basis for evaluating safety and efficacy. This support extends to trials of neurovascular and neurointerventional devices.

At Intrinsic Imaging, our CNS Imaging division brings together more than 100 board-certified, fellowship-trained neuroradiologists with expertise across the full spectrum of brain and spine disease, including Alzheimer's disease and other dementias, multiple sclerosis, Parkinson's and Huntington's diseases, epilepsy, stroke and cerebrovascular disease, traumatic brain injury, spinal cord injury, and degenerative disorders of the spine. Brain and spinal tumors are assessed in collaboration with our Oncology Imaging division.

Intrinsic Imaging supports CNS imaging endpoints across an extensive range of modalities, including structural and functional MRI, MRA, CT and CTA, CT and MR perfusion, diffusion and diffusion tensor imaging, PET and other nuclear imaging techniques, spectroscopy, catheter angiography, and transcranial Doppler ultrasound. Our teams work closely with sponsors from protocol development and imaging charter design through database lock to establish standardized acquisition requirements, qualify and train imaging sites, define quantitative and qualitative assessment methodologies, conduct blinded independent central reviews, and implement adjudication procedures designed to minimize inter- and intra-reader variability.

By combining neuroradiology subspecialty expertise with standardized imaging protocols, centralized quality control, and reproducible quantitative assessment, Intrinsic Imaging helps sponsors generate reliable, scientifically robust imaging data suitable for longitudinal endpoint evaluation, clinical development decision-making, and global regulatory submissions. This rigor is particularly valuable in CNS trials, in which subtle changes in anatomy, lesion burden, perfusion, diffusion, metabolism, or other imaging biomarkers may provide critical evidence of disease progression or therapeutic response.

Central Nervous System Imaging Division Highlights

  • Extensive experience in providing services in support of clinical trials involving the central nervous system.
  • 100+ board-certified, fellowship-trained neuroradiologists.
  • Expertise includes the full spectrum of brain and spine disease processes.
  • Modality expertise includes:
    • Catheter angiography with special expertise in invasive devices
    • CT & CTA including CT perfusion
    • Diffusion tensor imaging
    • MRI & MRA including MR perfusion
    • Nuclear imaging including FDG PET
    • Spectroscopy
    • Ultrasound including transcranial Doppler

Neuroimaging Endpoints for CNS Clinical Trials

At Intrinsic Imaging, our neuroimaging core lab supports clinical trials evaluating both the safety and the efficacy of investigational therapies and devices in Alzheimer's disease and other dementias, multiple sclerosis, Parkinson's and Huntington's diseases, epilepsy, stroke, traumatic brain injury, brain and spinal tumors, and spinal cord injury. Imaging endpoints are defined with sponsors during protocol and imaging charter development, then assessed by board-certified, fellowship-trained neuroradiologists using standardized quantitative and qualitative methods.

Typical assessments include lesion burden, structural change, perfusion, diffusion, metabolism, and other imaging biomarkers, which often serve as primary or secondary imaging endpoints in CNS trials. Intrinsic Imaging measures each biomarker consistently over time, so that small changes reflect true disease progression or therapeutic response.

Advanced MRI, PET and Perfusion Imaging

Intrinsic Imaging's neuroradiologists centrally read structural and functional MRI, MRA, CT and CTA, CT and MR perfusion, diffusion and diffusion tensor imaging, spectroscopy, FDG PET and other nuclear imaging, catheter angiography, and transcranial Doppler ultrasound. Readers are selected for each trial according to the indication, the imaging modality, and the assessment criteria the protocol specifies, giving sponsors subspecialty interpretation of every technique the study requires.

Controlling Variability in Multicenter Neuroimaging

Intrinsic Imaging applies site and scanner qualification, acquisition standardization, and centralized quality control to keep imaging data consistent across sites, scanners, and timepoints, allowing the subtle longitudinal changes that can be decisive in CNS trials to be measured with confidence. Blinded independent central review (BICR) is performed under single-, double-, or triple-read paradigms, with reader training and adjudication procedures designed to minimize inter- and intra-reader variability.

Neuroimaging Methods by Disease and Endpoint

Intrinsic Imaging aligns sequences, tracer selection, quantitative analysis, and central review with the indication and the role of each endpoint, enabling sponsors to distinguish disease progression, treatment effects, and imaging safety findings.

IndicationMethodsAssessments
Alzheimer’s disease and dementiaStructural MRI, amyloid PET, tau PET and FDG PETWhole-brain and hippocampal volume, regional tracer uptake and longitudinal change
Anti-amyloid treatment safetyFLAIR and susceptibility-sensitive MRIARIA-E edema or effusion and ARIA-H microhemorrhage or superficial siderosis
Multiple sclerosisT2/FLAIR, contrast-enhanced T1 and volumetric MRINew or enlarging lesions, enhancing lesions and brain-volume change
ALS and motor-neuron diseaseStructural MRI and diffusion tensor imagingRegional atrophy and white-matter measures as protocol-defined exploratory biomarkers
Parkinson’s and movement disordersMRI, dopamine-transporter SPECT and PETRegional structure, tracer binding and protocol-defined functional measures
Stroke and cerebrovascular diseaseCT/CTA, MRI/MRA and perfusion imagingASPECTS, infarct volume, vessel status and perfusion-defined tissue measures
Brain tumorsContrast-enhanced MRI, diffusion and perfusionRANO-based response, enhancing disease and non-enhancing change

ARIA Safety Review and Escalation

For anti-amyloid programs, Intrinsic Imaging's neuroradiologists assess amyloid-related imaging abnormalities (ARIA) using the protocol's severity definitions and comparison timepoints. Our readers distinguish ARIA-E from ARIA-H, document lesion location and extent, and track changes on follow-up MRI. Findings are communicated through an agreed safety-escalation process that gives investigators and sponsors consistent, timely safety information, while treatment decisions remain with the investigator and sponsor.

Volumetric MRI and Molecular Imaging Biomarkers

Intrinsic Imaging's quantitative workflows include brain and regional segmentation, hippocampal volumetry, lesion burden, diffusion measures, and PET uptake quantification. Registration, segmentation review, and acquisition checks help distinguish biological change from motion, scanner differences, or analysis artifacts. PET reference regions and any tracer-specific normalization methods are defined in the analysis plan, keeping regional uptake comparable across sites and timepoints.

Scanner Harmonization and Longitudinal Quality Control

Before enrollment begins, Intrinsic Imaging qualifies scanner configurations and standardizes sequences, positioning, and reconstruction, with phantom testing where the quantitative endpoint requires it. Scanner upgrades, protocol changes, and repeat examinations are documented so that their effects can be considered in the analysis.

Intrinsic Imaging's central readers follow prespecified blinding and comparison rules, with calibration cases and adjudication supporting consistent reads throughout the study. Image quality, missing sequences, and non-evaluable assessments are tracked alongside endpoint results, giving sponsors a traceable record of the data behind each endpoint.

Guidance for Sponsors

Physician-authored guidance from Intrinsic Imaging on imaging endpoints and trial design.

Illustration of the human muscular system

Guidance for Sponsors · Volume 4, Issue 9 · 2026 Edition

Muscular Dystrophy: Medical Imaging in Clinical Trials

MRI has become one of the most valuable tools for measuring disease in muscular dystrophy. It shows which muscles are involved, how severely and how actively, and it can guide biopsy and monitor therapy. Since the first edition of this issue, quantitative MRI has moved from grading scales to precise fat-fraction measurement, and muscle fat fraction has been shown to predict loss of ambulation in Duchenne muscular dystrophy. With new therapies now approved, MRI is a key secondary endpoint and a candidate surrogate for future trials.

Read the article
Illustration of a neuron

Guidance for Sponsors · Volume 5, Issue 3 · 2026 Edition

Functional Imaging of the Dopamine Pathway

Parkinson disease is rising rapidly worldwide, and its early diagnosis remains difficult: symptoms overlap with essential tremor, drug-induced parkinsonism and the atypical parkinsonian syndromes, and routine MRI is usually normal. Functional imaging of the presynaptic dopamine pathway, with DaTscan SPECT and Fluorodopa F 18 PET, makes the loss of dopaminergic neurons visible. European regulators have qualified dopamine transporter imaging as an enrichment biomarker for early Parkinson disease trials, and it now works alongside the alpha-synuclein seed amplification assay in a new biological definition of the disease. This issue explains how these tools work and how sponsors should use them.

Read the article
Illustration of neurons

Guidance for Sponsors · Volume 5, Issue 4 · 2026 Edition

Temporal Lobe Epilepsy and Volumetric MRI in Clinical Trials

Temporal lobe epilepsy caused by hippocampal sclerosis is one of the most common forms of drug-resistant focal epilepsy, and one of the most treatable when it is correctly identified. Visual reading of MRI can miss mild or bilateral hippocampal atrophy, which makes patient selection the weak link in many trials. Quantitative volumetry with FDA-cleared software, acquired on a harmonized epilepsy protocol, converts a subjective impression into a numerical biomarker. It can set inclusion thresholds, stratify severity, predict surgical outcome and, potentially, measure the effect of new drugs, ablation and neurostimulation devices.

Read the article

More guidance: Brain Tumor Imaging in Trials; Alzheimer's Neuroimaging in Trials; Traumatic Brain Injury Imaging in Trials; Contrast-Enhanced Neuroimaging in Trials

Browse all Guidance for Sponsors →

Featured Case Study

Intrinsic Imaging

Central Nervous System

Phase II Alzheimer's Amyloid PET and MRI

  • 55 sites
  • 3T MRI, amyloid PET
  • Volumetric and visual PET endpoints

Challenge

In a Phase II Alzheimer's disease program, the trial's biomarker endpoints depended on detecting subtle changes in brain volume and amyloid burden over time. Yet the 55 participating academic and commercial imaging centers operated scanners from multiple vendors, each introducing its own measurement variability into volumetric MRI quantification and amyloid PET assessment. Without adequate control, this cross-site variability could obscure treatment-related changes and compromise interpretation of both the secondary and exploratory biomarker endpoints.

Read the case study
View all case studies

Frequently Asked Questions

Who leads imaging operations at Intrinsic Imaging?
Heekwan Lee serves as Senior Vice President of Imaging Operations at Intrinsic Imaging, with responsibility for operational strategy, scientific oversight, regulatory compliance and execution of AI-enabled imaging clinical trials. He also serves as Intrinsic Imaging’s principal subject matter expert for artificial intelligence applications in medical imaging.
Which imaging modalities does Intrinsic Imaging’s technology support?
Intrinsic Imaging’s technology workflow accommodates DICOM and other study imaging across CT, MRI, PET/CT, SPECT, radiography, ultrasound, echocardiography, DXA, OCT, fundus imaging, angiography, endoscopy and protocol-specific formats. Intrinsic Imaging selects configurations, quality checks and assessment tools for each study rather than imposing a single generic workflow.
How does Intrinsic Imaging select readers for medical imaging AI studies?
Intrinsic Imaging selects reader panels according to the clinical indication, imaging modality, intended use and regulatory objectives. Intrinsic Imaging draws on more than 650 board-certified, fellowship-trained physicians to assemble appropriately qualified panels.
Go to more Frequently Asked Questions

Tell us about your trial.

Planning a Central Nervous System trial? Our team will respond within one business day.